Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$2.17 +1.9%	$1.42	$0.69 ▼ $3.94	$429.46M	0.82	5.26 million shs	4.87 million shs
REPL Replimune Group	$5.67 +1.3%	$7.78	$2.68 ▼ $17.00	$437.11M	0.67	17.49 million shs	2.27 million shs
RGNX REGENXBIO	$9.01 +11.1%	$8.52	$5.03 ▼ $13.48	$409.67M	1.11	680,725 shs	1.36 million shs
SKYE Skye Bioscience	$3.29 -7.3%	$3.68	$1.14 ▼ $7.47	$110.01M	2.21	299,094 shs	488,202 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	+1.88%	+5.85%	+63.16%	+174.58%	+23.30%
REPL Replimune Group	+1.25%	+1.98%	+69.76%	-32.10%	-44.79%
RGNX REGENXBIO	+11.10%	+2.15%	-0.88%	-7.21%	-26.21%
SKYE Skye Bioscience	-7.32%	-6.27%	-24.54%	+73.16%	-40.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	3.5664 of 5 stars	3.4	1.0	3.9	1.1	1.7	0.6
REPL Replimune Group	4.4412 of 5 stars	4.2	2.0	4.5	1.7	2.5	0.6
RGNX REGENXBIO	4.3747 of 5 stars	3.4	3.0	4.6	2.3	2.5	0.6
SKYE Skye Bioscience	1.9963 of 5 stars	3.6	2.0	0.0	2.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	222.58% Upside
REPL Replimune Group	2.33	Hold	$7.67	35.21% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$28.38	214.93% Upside
SKYE Skye Bioscience	3.14	Buy	$15.50	371.12% Upside

Current Analyst Ratings Breakdown

Latest SKYE, REPL, ESPR, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$34.00
8/15/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
8/8/2025	RGNX REGENXBIO	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $17.00
8/8/2025	RGNX REGENXBIO	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $37.00
8/8/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	1.32	$0.02 per share	88.65	($2.15) per share	-1.01
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A
RGNX REGENXBIO	$83.33M	5.46	N/A	N/A	$4.23 per share	2.13
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.49	N/A	N/A	N/A	-35.84%	-0.91%	-28.41%	11/6/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	11/11/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.44	N/A	N/A	N/A	-112.70%	-66.95%	-34.14%	11/5/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$1.06	N/A	N/A	N/A	N/A	-76.03%	-69.20%	N/A

Latest SKYE, REPL, ESPR, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	-$1.38	-$0.25	-$1.38	$40.87 million	$21.36 million
8/7/2025	Q2 2025	SKYE Skye Bioscience	-$0.34	-$0.44	-$0.10	-$0.44	N/A	N/A
8/5/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	-$0.02	+$0.15	-$0.02	$62.55 million	$82.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.15	0.76
REPL Replimune Group	0.21	6.94	6.94
RGNX REGENXBIO	N/A	3.13	3.13
SKYE Skye Bioscience	N/A	6.09	6.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
REPL Replimune Group	92.53%
RGNX REGENXBIO	88.08%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
REPL Replimune Group	5.20%
RGNX REGENXBIO	12.79%
SKYE Skye Bioscience	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	201.62 million	198.20 million	Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable
RGNX REGENXBIO	370	50.51 million	44.05 million	Optionable
SKYE Skye Bioscience	11	30.99 million	29.59 million	Optionable

SKYE, REPL, ESPR, and RGNX Headlines

Recent News About These Companies

Skye Bioscience, Inc. to Present at Multiple Investment and Medical Conferences in September 2025

August 21 at 7:51 AM | quiverquant.comQ

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

August 21 at 7:00 AM | globenewswire.com

Skye Bioscience (NASDAQ:SKYE) Upgraded by Evercore ISI to Strong-Buy Rating

August 18, 2025 | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Raised to "Strong-Buy" at Evercore ISI

August 17, 2025 | americanbankingnews.com

Evercore ISI Group Initiates Coverage of Skye Bioscience (SKYE) with Outperform Recommendation

August 16, 2025 | msn.com

Evercore starts Skye Bioscience at Outperform on nimacimab potential

August 14, 2025 | msn.com

Skye Bioscience initiated with an Outperform at Evercore ISI

August 14, 2025 | msn.com

Skye Bioscience, Inc. (NASDAQ:SKYE) is Altium Capital Management LLC's 9th Largest Position

August 14, 2025 | marketbeat.com

Skye Bioscience Earnings Call: Positive Outlook Amid Challenges

August 13, 2025 | msn.com

Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform

August 9, 2025 | msn.com

Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ...

August 9, 2025 | finance.yahoo.com

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

August 7, 2025 | globenewswire.com

We Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth Carefully

August 6, 2025 | finance.yahoo.com

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

July 30, 2025 | globenewswire.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Analysts

July 28, 2025 | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Shares Down 8% - What's Next?

July 25, 2025 | marketbeat.com

SKYE Stock Price Quote | Morningstar

July 11, 2025 | morningstar.comM

Skye Bioscience, Inc. (SKYE) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Skye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a Data

July 6, 2025 | msn.com

Positive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past year

June 25, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SKYE, REPL, ESPR, and RGNX Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$2.17 +0.04 (+1.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.17 0.00 (0.00%)

As of 08/22/2025 07:57 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Replimune Group NASDAQ:REPL

$5.67 +0.07 (+1.25%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.74 +0.07 (+1.15%)

As of 08/22/2025 07:59 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REGENXBIO NASDAQ:RGNX

$9.01 +0.90 (+11.10%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.02 +0.01 (+0.11%)

As of 08/22/2025 04:46 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Skye Bioscience NASDAQ:SKYE

$3.29 -0.26 (-7.32%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.39 +0.10 (+3.04%)

As of 08/22/2025 07:57 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time